Results 221 to 230 of about 435,470 (309)

Emerging Microbiome-Based Therapies for Skin Infections: From Probiotics and Prebiotics to Synthetic Microbiome Engineering. [PDF]

Infect Drug Resist
Brar GS, Sharma A, Siddiqui AJ, Sharma L.   +3 more
europepmc   +1 more source

Chlorella vulgaris biorefineries: sustainable biofuels and high‐value carbon capture

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Global reliance on fossil fuels has created urgent economic and environmental challenges, yet large‐scale use of algal biomass remains limited by production costs. Industrial scaling is constrained by inefficient harvesting and the technical challenges of processing recalcitrant cell walls.
Sandyelle Ferreira Alcântara Araújo, Antonio Átila Menezes Ferreira, Lucia Andrea Sindeaux de Oliveira, Dayana Nascimento Dari, Devany Quintela Soares, Eliana Elisa Francelino Mavie, Francisco Leonardo Alves de Moraes Sousa, Jessica Lopes da Silva, João Vitor Gomes de Araújo Silva, Thiago Queiroz da Silva, Ana Karine Portela Vasconcelos, Kelma Maria dos Santos Pires Cavalcante, John Hebert da Silva Felix, José Cleiton Sousa dos Santos   +13 more
wiley   +1 more source

Interaction between tick and host microbiotas: a four-step waltz. [PDF]

Parasit Vectors
Baquer F, Grillon A.
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Cosmetic Interventions for Skin Microbiome Modulation: Current Strategies and Future Directions. [PDF]

Skin Res Technol
Taléns-Visconti R, Diez-Sales O, Nácher A.   +2 more
europepmc   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

An Unusual Presentation of Cutaneous Leishmaniasis in a Patient with Substance Use: A Diagnostic and Management Case Report. [PDF]

Clin Case Rep
Pazoki H, Soleymani E, Kordi S, Fakhar M.   +3 more
europepmc   +1 more source

Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION project

British Journal of Clinical Pharmacology, EarlyView.
Aims Amoxicillin, a widely used β‐lactam antibiotic, requires improved pharmacokinetic characterization during breastfeeding. This study used a population pharmacokinetic (PopPK) approach to model amoxicillin concentrations in breast milk, identify variability sources and estimate infant exposure, applying worst‐case scenarios.
Sarah Baklouti, Virginie Rigourd, Alice Panchaud, Hedvig Nordeng, Karel Allegaert, Pieter Annaert, Miao‐Chan Huang, Anaelle Monfort, Monia Guidi, Peggy Gandia   +9 more
wiley   +1 more source

Fatal Necrotizing Soft Tissue Infection Following Continuous Glucose Monitoring in a Patient with Type 1 Diabetes: A Case Report and Literature Review. [PDF]

Diseases
Popazu C, Voineag C, Grigore I, Șerban C, Guliciuc M, Voicu D, Toma A.   +6 more
europepmc   +1 more source

Lack of improvement after short‐term topical antistaphylococcal endolysin SA.100 therapy in patients with mild‐to‐moderate atopic dermatitis: Results from a randomized, vehicle‐controlled trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Atopic dermatitis (AD) is a chronic immune‐mediated inflammatory skin disease. An overgrowth of Staphylococcus aureus (S. aureus) and decreased microbial diversity is apparent in 70%–90% of AD patients. SA.100 is a recombinant endolysin targeting S. aureus that might be a novel treatment for patients with mild‐to‐moderate AD.
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Ismahaan Abdisalaam, Rianne Rijneveld, Erica S. Klaassen, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Benthe Freyee, Karin Platenkamp, Mariette E. van Poelgeest, Robert Rissmann, Martijn B. A. van Doorn, Tessa Niemeyer – van der Kolk   +15 more
wiley   +1 more source